1 additional year of workNovartis Pharmaceuticals Corporation Investment Savings Plan is a defined contribution plan with a profit-sharing component and 401k feature. This plan has a BrightScope Rating of 88, placing it in the top 15% of all plans in its peer group. This plan is also in the top 15% of plans for Account Balances, Company Generosity, Investment Menu Quality, Salary Deferral, and Total Plan Cost. Novartis Pharmaceuticals Corporation Investment Savings Plan currently has over 25,500 active participants and over $3.3B in plan assets.
| Address |
230 Park Avenue, 21st Floor
New York, NY 10169 |
| Industry | Manufacturing |
| Administrator | William A. Flannery, Exec Director |
| Net Plan Assets | $3,290,000,000 |
| Total Participants | 26,000 |
| Avg Account Balance | $130,000 |
| Amgen | 89.0 |
| Bayer | 87.4 |
| Bristol-Myers Squibb Company | 87.2 |
| Merck & Co. | 83.9 |
| Merck & Co. | 83.5 |
| Eli Lilly and Company | 79.2 |
| 1. | Fidelity Trust Interest Income | 14% |
| 2. | Fidelity Trust Large Cap Index | 11% |
| 3. | Fidelity Trust International | 6% |
BrightScope Rating
Comments